Avivagen to Attend Bloom Burton & Co. Healthcare Investor Conference
OTTAWA, ONTARIO, June 18, 2012 - Avivagen Inc. (TSX Venture Exchange: VIV), a company developing animal and human applications centered on the novel immune function effects of its proprietary and patented oxidized carotenoid technology, today announced that Dr. Graham Burton, the Company's President, will attend the Bloom Burton & Co. Healthcare Investor Conference on Thursday, June 21. at the Toronto Board of Trade in Toronto, Ontario.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian public and private companies through presentations and break-out Q&A sessions.
About Avivagen
Avivagen, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Avivagen is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.avivagen.com and www.chemaphor.com.
About Bloom Burton & Co. Bloom Burton & Co. is Canada's largest and most active healthcare-specialized investment banking group. The team of healthcare specialists merges scientific, medical, clinical, intellectual property and commercial expertise with a strong understanding of the capital markets, to advise and raise capital for private and public companies. For more information, please visit www.bloomburton.com.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David HankinsonGraham Burton, PhD
CEO, Avivagen Inc.President and Co-Founder, Avivagen Inc.
Phone: 902-825-9270Phone: 613-990-0969
d.hankinson@avivagen.comg.burton@avivagen.com
Copyright (c) 2012 Thenewswire.ca - All rights reserved.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.